clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Katelaris PH et al. | Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848659 |
Ammon S et al. | Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848660 |
Leiper K et al. | Open label trial of oral clarithromycin in active Crohn's disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848665 |
Dalla Libera M et al. | High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication. | 1996 | Aliment. Pharmacol. Ther. | pmid:8730251 |
Labenz J et al. | One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8730252 |
Huang J et al. | Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. | 2013 | Aliment. Pharmacol. Ther. | pmid:24117692 |
Molina-Infante J et al. | Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. | 2010 | Aliment. Pharmacol. Ther. | pmid:20180787 |
Chacko Y and Holtmann GJ | Helicobacter pylori eradication and weight gain: has it opened a Pandora's box? | 2011 | Aliment. Pharmacol. Ther. | pmid:21679208 |
Murakami K et al. | Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. | 2002 | Aliment. Pharmacol. Ther. | pmid:12390102 |
Zullo A et al. | High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. | 2005 | Aliment. Pharmacol. Ther. | pmid:15948808 |
Gisbert JP et al. | 7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure. | 2005 | Aliment. Pharmacol. Ther. | pmid:15882246 |
Nista EC et al. | Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. | 2005 | Aliment. Pharmacol. Ther. | pmid:15882245 |
Gisbert JP and Calvet X | Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. | 2012 | Aliment. Pharmacol. Ther. | pmid:22129228 |
Bühling A et al. | Influence of anti-Helicobacter triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora. | 2001 | Aliment. Pharmacol. Ther. | pmid:11552917 |
Hokari K et al. | Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. | 2001 | Aliment. Pharmacol. Ther. | pmid:11552922 |
Dani R et al. | Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. | 1999 | Aliment. Pharmacol. Ther. | pmid:10594400 |
Harris A | The importance of clarithromycin dose in the management of H. pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10594406 |
Lehmann FS et al. | Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:10735923 |
Miwa H et al. | Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10735925 |
Spinzi GC et al. | Seven-day triple therapy with ranitidine bismuth citrate or omeprazole and two antibiotics for eradication of Helicobacter pylori in duodenal ulcer: a multicentre, randomized, single-blind study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10735926 |
Graham DY et al. | Furazolidone combination therapies for Helicobacter pylori infection in the United States. | 2000 | Aliment. Pharmacol. Ther. | pmid:10651662 |
Wong BC et al. | Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10651663 |
Harris AW et al. | Eradication of Helicobacter pylori with lansoprazole and clarithromycin. | 1995 | Aliment. Pharmacol. Ther. | pmid:7605863 |
Katelaris PH et al. | A randomized prospective comparison of clarithromycin versus amoxycillin in combination with omeprazole for eradication of Helicobacter pylori. | 1995 | Aliment. Pharmacol. Ther. | pmid:7605864 |
Malfertheiner P et al. | Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. | 2003 | Aliment. Pharmacol. Ther. | pmid:12969088 |
Hassan C et al. | Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. | 2003 | Aliment. Pharmacol. Ther. | pmid:12969091 |
Sheu BS et al. | Impact of intravenous omeprazole on Helicobacter pylori eradication by triple therapy in patients with peptic ulcer bleeding. | 2002 | Aliment. Pharmacol. Ther. | pmid:11856088 |
Huang J and Hunt RH | The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383500 |
Miwa H et al. | Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383502 |
Ducóns JA et al. | Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383507 |
Calvet X et al. | Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383508 |
Sieg A et al. | Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383519 |
Cestari R | Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with Helicobacter pylori infection. H. Pylori Lombardy Group. | 1998 | Aliment. Pharmacol. Ther. | pmid:9798804 |
Wong BC et al. | Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. | 2001 | Aliment. Pharmacol. Ther. | pmid:11736727 |
Iijima K et al. | Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria. | 2004 | Aliment. Pharmacol. Ther. | pmid:15153171 |
Spadaccini A et al. | Omeprazole versus ranitidine: short-term triple-therapy in patients with Helicobacter pylori-positive duodenal ulcers. | 1996 | Aliment. Pharmacol. Ther. | pmid:8899094 |
Perri F et al. | Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'. | 2003 | Aliment. Pharmacol. Ther. | pmid:14535875 |
Sheu BS et al. | Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. | 2005 | Aliment. Pharmacol. Ther. | pmid:15691303 |
Savarino V et al. | A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics. | 1997 | Aliment. Pharmacol. Ther. | pmid:9305478 |
Williams MP et al. | Seven-day treatment for Helicobacter pylori infection: ranitidine bismuth citrate plus clarithromycin and tetracycline hydrochloride. | 1997 | Aliment. Pharmacol. Ther. | pmid:9305479 |
Janssen MJ et al. | A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. | 2001 | Aliment. Pharmacol. Ther. | pmid:11328254 |
Broutet N et al. | Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. | 2003 | Aliment. Pharmacol. Ther. | pmid:12492738 |
Chi CH et al. | Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. | 2003 | Aliment. Pharmacol. Ther. | pmid:12895220 |
Higuchi K et al. | Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. | 2003 | Aliment. Pharmacol. Ther. | pmid:12492739 |
Coelho LG et al. | Once-daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients. | 2003 | Aliment. Pharmacol. Ther. | pmid:12492742 |
Zullo A et al. | Clarithromycin or levofloxacin in the sequential therapy for H. pylori eradication? | 2010 | Aliment. Pharmacol. Ther. | pmid:20518756 |
Gisbert JP and Pajares JM | Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. | 2002 | Aliment. Pharmacol. Ther. | pmid:12030945 |
Laine L and Dhir V | Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:12030957 |
Vallve M et al. | Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. | 2002 | Aliment. Pharmacol. Ther. | pmid:12030958 |
Colin R | Duodenal ulcer healing with 1-week eradication triple therapy followed, or not, by anti-secretory treatment: a multicentre double-blind placebo-controlled trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:12030959 |